Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
3rd February 2026 Uncategorised 0
The company will initially develop a vaccine to tackle colorectal and pancreatic cancers

More: Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
Source: News
